Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

• by Shahram Salek-Ardakani

• June 2, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

• by Amy S. Paller, Danielle Marcoux, Michele Ramien, Eulalia Baselga, Vania Oliveira de Carvalho, Ledit R. F. Ardusso, Marlies de Graaf, Suzanne Pasmans, Mirna Toledo-Bahena, Cory J. Rubin, Joel C. Joyce, Lara Wine Lee, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang

• April 17, 2026

Correction: Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report

• by Xiaofan Liao, Yuan Lu

• August 18, 2026